Odc is highly expressed in neuroblastoma and has a short half-life with rapid proteolytic turnover, so despite DFMO being an irreversible inhibitor, higher DFMO exposures are required for clinically relevant Odc inhibition. The gene discussed is ODC1; the disease is neuroblastoma.